Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 6,316 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Standard ADT, Dovitinib
Drug
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
Conditions
Diabetes, Hypertension, Hyperlipidemia
Interventions
Health coaching by medical assistants in primary care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Houston, Texas
Conditions
Primary or Metastatic Lung Tumors
Interventions
AuroLase Therapy
Device
Lead sponsor
Nanospectra Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Determinants of POTS - Pilot1

NCT04050410
Conditions
Postural Tachycardia Syndrome
Interventions
Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Hereditary Angioedemas
Interventions
No intervention
Other
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Saint Charles, Illinois + 4 more
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
Interventions
surgical procedure, astatine At 211 monoclonal antibody 81C6
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Dalantercept, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Fort Collins, Colorado • Hartford, Connecticut • New Britain, Connecticut + 27 more
Conditions
Migraine
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Orthostatic Hypotension
Interventions
water 16 fl oz
Other
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hypertension
Interventions
Supported HBPM program plus multifaceted implementation strategy, Usual care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
23,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New York, New York
Completed Not applicable Interventional

Learning to THRIVE (L2T) Program Pilot

NCT07797010
Conditions
Interstitial Cystitis and Bladder Pain Syndrome
Interventions
Learning to THRIVE (L2T) Program
Behavioral
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of Fenofibrate for PSC

NCT01142323
Conditions
Primary Sclerosing Cholangitis
Interventions
fenofibrate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
Completed Not applicable Interventional Accepts healthy volunteers

Hand Hygiene Randomized Cluster Intervention to Reduce Infections

NCT02131727
Conditions
Respiratory Tract Infections, Gastrointestinal Infections
Interventions
Hand Hygiene Improvement Intervention, Ask Me 3
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kent, Ohio
Conditions
HIV Infections, Electronic Health Record, Primary Health Care
Interventions
EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Interventions
8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin